Compare Inovio Pharmaceuticals Inc (INO) vs Direxion Daily S&P 500 Bull 3X Shares (SPXL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Direxion Daily S&P 500 Bull 3X Shares trades at $267.7. The key difference: Direxion Daily S&P 500 Bull 3X Shares is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | SPXL | |
|---|---|---|
Market Cap | $89.27M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $2.87 | $288.04 |
52-Week Low | $1.05 | $170.20 |
Enterprise Value | $60.28M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
SPXL, a leveraged ETF tracking the S&P 500, trades at $264.57, down 0.44% on the day amid broader market weakness. Technical indicators signal a bearish bias with moving averages pointing lower, though oscillators remain neutral. Recent news highlights concerns about S&P 500 valuation and AI-driven concentration risks, with the index facing pressure from chip stock declines and macroeconomic uncertainty.
The outlook hinges on S&P 500 performance, with earnings season and economic data as key catalysts. Risks include market overvaluation and sector concentration, but analyst targets suggest potential upside if bullish forecasts materialize. Investors must weigh leveraged exposure against volatility and broader index trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Direxion Daily S&P 500 Bull 3X Shares
SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →
